Chicago Capital sold 377,850 shares of PRCT in the fourth quarter; the estimated transaction value was $12.53 million based on quarterly average pricing. Meanwhile, the quarter-end position value ...

The MarketWatch News Department was not involved in the creation of this content. Results of 244-Patient Study to Support Planned FDA Pre-Market Approval (PMA) Application BOSTON and YOKNEAM, Israel, ...

BOSTON and YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- Butterfly Medical, developer of a proprietary non-surgical solution for benign prostatic hyperplasia (BPH), today announced the successful ...

UCHealth Longs Peak Hospital in Longmont, Colo., is using a robot-assisted procedure that incorporates AI to treat benign prostatic hyperplasia, or BPH, a common condition among older men. The ...

Randomized controlled trials (RCTs) are considered the gold standard for evaluating surgical interventions for benign prostatic hyperplasia (BPH). However, the validity and reliability of their ...

In a trial, the newly approval urethral stent provided significant and durable relief of BPH-related LUTS over 12 months. The FDA has approved the ProVee® System for treatment of benign prostatic ...

DEAR DR. ROACH: I have benign prostatic hyperplasia (BPH), and I am taking tamsulosin daily. It works and helps with my daily urination. How long should I continue to take it? Are there any related ...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc. announced today the U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring(R) Implant and Delivery System ...

DEAR DR. ROACH: I have benign prostatic hyperplasia (BPH), and I am taking tamsulosin daily. It works and helps with my daily urination. How long should I continue to take it? Are there any related ...

DUBLIN, Dec. 9, 2025 /PRNewswire/ -- ProVerum Limited, a medical device company focused on innovative, safe and effective solutions for treating benign prostatic hyperplasia (BPH), today announced it ...